$1.75+0.11 (+6.71%)
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
PepGen Inc. in the Healthcare sector is trading at $1.75. The stock is currently near its 52-week low of $1.01, remaining 56.4% below its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why PEPG maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-co...
PepGen (NASDAQ:PEPG) reported top-line results from the lowest-dose cohort of its Phase II FREEDOM2 multiple ascending dose (MAD) study evaluating PGN-EDO-DM1 in myotonic dystrophy type 1 (DM1), highlighting what management characterized as encouraging safety, splicing, and functional trend data. F
The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.
The mean of analysts' price targets for PepGen (PEPG) points to a 75.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
Key Insights PepGen's significant individual investors ownership suggests that the key decisions are influenced by...